BioTime, Inc. (BTX) Holdings Boosted by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. grew its position in BioTime, Inc. (NYSEAMERICAN:BTX) by 36.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 143,800 shares of the biotechnology company’s stock after acquiring an additional 38,400 shares during the period. Schwab Charles Investment Management Inc.’s holdings in BioTime were worth $310,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Broadwood Capital Inc. boosted its position in shares of BioTime by 0.6% in the third quarter. Broadwood Capital Inc. now owns 27,279,254 shares of the biotechnology company’s stock worth $77,473,000 after purchasing an additional 160,000 shares during the period. State Street Corp boosted its position in shares of BioTime by 10.3% in the second quarter. State Street Corp now owns 1,345,379 shares of the biotechnology company’s stock worth $4,238,000 after purchasing an additional 125,833 shares during the period. GSA Capital Partners LLP boosted its position in shares of BioTime by 124.1% during the third quarter. GSA Capital Partners LLP now owns 174,816 shares of the biotechnology company’s stock worth $496,000 after acquiring an additional 96,816 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of BioTime by 29.8% during the third quarter. Dimensional Fund Advisors LP now owns 156,721 shares of the biotechnology company’s stock worth $445,000 after acquiring an additional 35,970 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of BioTime by 95.6% during the third quarter. Jane Street Group LLC now owns 44,548 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 21,778 shares during the last quarter.

How to Become a New Pot Stock Millionaire

Shares of NYSEAMERICAN:BTX opened at $2.69 on Monday. BioTime, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $3.59.

A number of equities analysts recently weighed in on BTX shares. Lake Street Capital started coverage on shares of BioTime in a research report on Friday, February 2nd. They set a “buy” rating and a $8.00 target price for the company. Zacks Investment Research lowered shares of BioTime from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. Three equities research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $5.75.

ILLEGAL ACTIVITY WARNING: This piece was first published by WKRB News and is the property of of WKRB News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/04/02/biotime-inc-btx-holdings-boosted-by-schwab-charles-investment-management-inc.html.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply